<DOC>
	<DOCNO>NCT00877877</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish necessary cause cervical cancer . This study design evaluate long-term immunogenicity safety 580299 HPV vaccine 10 year administration first dose HPV vaccine ( Month 0 ) administer primary study 580299/013 . This protocol post deal objective &amp; outcome measure extension phase Month 60 Month 120 . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT00196924 ) . The objective &amp; outcome measure extension phase Month 48 present separate protocol posting ( NCT00316706 ) .</brief_summary>
	<brief_title>Evaluation Long-term Immunogenicity Safety Human Papillomavirus ( HPV ) Vaccine Healthy Female Subjects .</brief_title>
	<detailed_description>Subjects age 10-14 year time entry primary study . No vaccine administer extension study . Results outcome measure describe analysis study report record . Please refer record mention respective outcome measure title .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parent legally acceptable representative ( LAR ) comply requirement protocol enrol study . A female enrol immunogenicity subset study 580299013 , receive three dos HPV vaccine participate extension study 580299013 . Written inform assent obtain subject . For subject legal age consent , write informed consent must obtain parent legally acceptable representative subject . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Use investigational nonregistered product ( drug vaccine ) plan use study period . Administration plan administration HPV vaccine , vaccine administer study 580299013 . Chronic administration immunosuppressant immunemodifying drug occur within three month precede study entry . Administration immunoglobulins and/or blood product occur within three month precede study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HPV vaccine</keyword>
	<keyword>cervical cancer</keyword>
</DOC>